LifeBridge Health (LBH) Institutional Review Board (IRB) is responsible for protecting the rights and welfare of human participants in research conducted by faculty, staff and residents affiliated with LifeBridge Health, Inc.
The IRB ensures the protections of the rights and welfare of human research subjects based on the rules and regulations of the Department of Health and Human Services (specifically Office for Human Research Protections) and the Food and Druga Administration (FDA) by approving, requiring modifications in, or disapproving Human Subject Research projects.
LifeBridge Health has one active IRB composed of members from various disciplines in the medical, social, and behavioral sciences, as well as community members. Within LifeBridge Health, an IRB must review all research involving human participants, and the research cannot begin until the IRB has reached a determination; even if the researcher perceives there are no risks for participants.
LifeBridge Health conducts human subject research under its Federalwide Assurance (FWA) issued by the Office of Human Research Protections (OHRP). The LBH IRB complies with the registration requirements for both OHRP and the FDA. For those interested in viewing the registration, LBH’s IRB registration number is IRB00002996 and its FWA number is FWA00003667.
LifeBridge Health IRB members are selected for their willingness to serve, expertise and familiarity with research design and procedures. IRB members include faculty from a wide variety of clinical disciplines and specialties to ensure adequate expertise, legal advisors, pharmacists, nurses, bioethicists, and others to provide needed expertise. Community members and non-scientists also contribute as voting members of the LBH IRB in order to reflect the viewpoint of the general community and lay audience.
The LifeBridge Health IRB aims to maintain a diverse roster in order to review the wide variety of research conducted within LifeBridge Health. The membership of LBH IRB complies with all federal regulatory requirements.
Chairperson
Department of Neuro Critical Care Sinai Hospital of Baltimore Board Certified – Neurology
Vice-Chairperson
Director of Pediatric Research Sinai Hospital Sinai Hospital of Baltimore Board Certified – Pediatrics Board Certified – Pediatric Hematology/Oncology
Intensivist, Critical Care Intensivist, Critical Care Medicine Sinai Hospital of Baltimore
Executive VP, Drug Development, MyMD Pharmaceuticals Former Director of Clinical Research and Scientific Grants for LBH
Pediatric Intensive Care Unit Sinai Hospital of Baltimore
Rubin Institute of Advance Orthopedics Sinai Hospital of Baltimore Board Certified – Orthopedic Surgery
Non-Affiliated QC Scientist II
Director of Maternal Fetal Medicine Obstetrics and Gynecology Sinai Hospital of Baltimore
Pharmacy Sinai Hospital of Baltimore
Inpatient Pharmacy Sinai Hospital of Baltimore
Non-affiliated Specialty in Bioethics
Former Member Sinai Hospital, Board of Directors Past President, Sinai Hospital Auxiliary
Director of Corporate Development Sinai Hospital of Baltimore
Department of Research Sinai Hospital of Baltimore
The LifeBridge Health IRB is available for questions, complaints, and general inquiries via email. Individuals are welcome to contact the IRB if their questions, concerns, or complaints are not being sufficiently answered by a research team, unable to reach the research team, would prefer to talk to someone besides the research team, have questions about their rights as a research participant, or want to obtain or provide their input about a research study in which they are participating in. Please contact us at lbhresearch@lifebridgehealth.org.
The LBH IRB meets the fourth Wednesday of each month, from 8:15 am to 10:15 am, unless otherwise notified. Any submissions requiring full board approval must be complete and ready for convened review at least 2-weeks prior to the next IRB Meeting.
| Submission Deadline | Meeting Date |
|---|---|
| January 10, 2024 | January 24, 2024 |
| February 14, 2024 | February 28, 2024 |
| March 13, 2024 | March 27, 2024 |
| April 10, 2024 | April 24, 2024 |
| May 8, 2024 | May 22, 2024 |
| June 5, 2024 | June 19, 2024 |
| July 10, 2024 | July 24, 2024 |
| August 7, 2024 | August 28, 2024 |
| September 11, 2024 | September 25, 2024 |
| October 9, 2024 | October 23, 2024 |
| November 6, 2024 | November 20, 2024 |
| December 11, 2024 | December 18, 2024 |
